# Particle Physics Techniques Applied to Health

## Paulo Crespo<sup>1,2</sup>





LIP training internship

LIP – July 6<sup>th</sup>, 2023


crespo@lip.pt

# Outline

- I Advances in Nuclear Medicine
  - 1. RPC-based TOF-PET
  - 2. Development of New Gamma Cameras
- II Advances in Imaging in Proton Radiotherapy
  - 1. Motivation
  - 2. Rationale for in-vivo imaging in proton radiotherapy (RT)
  - 3. The multi-slat concept for prompt-gamma imaging in proton RT
  - 4. In-beam time-of-flight PET for proton RT

# Rationale is based on state-of-the-art of PET (positron emission tomography):


• Technique experiences growing utilization in nuclear medicine, e.g. for diagnostic/screening/staging of oncologic, neurologic, and cardiac disease.




- E.g. Palmisano et al. Saudi J Gastroenterol 2011
- F, 64 a., symptoms: palpable supracavicular, ganglionic adenopathies, asthenia, anorexia.
- PET-based diagnostic: adenocarcinoma of the ascendent colon.

## I - 1. RPC-based TOF-PET Rationale:

 PET technology is extremely costly (millions of €); patient examinations are equally costly (ca. 4000 €), lengthy in time, morphologically imprecise, often inconclusive when imaging small lesions (detectability, sensitivity, and specificity); and the patient bears a non-negligible amount of radiation dose.



I - 1. RPC-based TOF-PET



LIP, July 6<sup>th</sup>, 2023

# I - 1. RPC-based TOF-PET




LIP, July 6<sup>th</sup>, 2023


# I - 1. RPC-based TOF-PET

## Implementation (software):


• R&D in simulation and reconstruction



# I - 1. Brain HiRez RPC-PET



# I - 1. Brain HiRez RPC-PET




- Collaboration between Laboratório de Instrumentação e Física Experimental de Partículas, LIP and the Universitary Hospital of Coimbra – **Nuclear Medicine Department**
- Gamma cameras are used to perform **scintigraphy**: a medical imaging modality used to obtain functional images. E.g. cardiology, pneumology, oncology (staging of tumors, evaluate therapeutic response)




Heart

study

#### Bone scans



Lung scintigraphy



#### **Kidneys** study

Mid

Mid

Rest


Systole

Stress


Diastole

Areas without

normal blood flow



## Gamma camera working principle




## Collimators prototypes




<sup>0</sup> **COIMBRA** 


Parallel-holes collimator (hexagones 0.5 mm "diameter)




LIP, July 6<sup>th</sup>, 2023

### Made of tungsten using Selective laser melting







- Specification by João Marcos
- Designed by Eng. Rui Alves (LIP mechanical workshop)
- Manufactured by M&I Materials


## Collimators prototypes




Pinhole collimator (1 mm hole, 0.5 mm channel edge height)


Made of Tungsten alloy (95.5% W, 4.5% Co)

- Specification by João Marcos
- **Designed** by DURIT (Albergaria-a-Velha)
- Manufactured by DURIT










## Phantom imaging




#### 1 2 9 0 UNIVERSIDADE D COIMBRA




### Pinhole collimator

Event density vs XY 150 15 10 40 30 20 -5 -10 10 -15 10 15 X, mm -15 -10 -5 0 5


### Parallel-hole collimator




### Crossed capillary tubes phantom








#### Event density vs XY




# II - 1. Motivation: Proton therapy physical advantage over photons




## Some evidence of advantages of PT over state-of-the-art X-rays

### Low-grade glioma, female, 38 y.o.: dose reduction accepted as being clinically relevant

Two-field intensity modulated PT



Volumetric intensity modulated arc therapy





van der Weide et al., Radiother Oncol (2020)

## Some evidence of advantages of PT over state-of-the-art X-ray therapy

### Pediatric medulloblastoma: Dose to 50% of the heart volume was reduced from 29.5% for IMRT to 0.5% for protons

IMRT – intensity modulated radiation therapy






ΡΤ

Clair et al., IJROBP

(2004)

# II - 1. Motivation: Proton therapy clinical benefits



#### Lung

**56% relative reduction** in incidences of grade 3 esophagitis

50% reduction in relative risk of recurrence

**Higher radiation dose** to the tumor while reducing risks of overall side effects

64% relative increase in 5-year overall survival

### **Esophageal**

3 to 4-day reduction in average hospital stay
5.1-22.8% overall reduction in pulmonary complications
68% relative reduction in wound complications

### **Prostate**

4.9% higher overall 5 year survival rate

35% less radiation to bladder and 59% less radiation to the rectum

**Proton patients** are almost twice as likely to report **treatment had NO IMPACT on their quality of life** compared to surgery, conventional radiation, and brachytherapy

Half as many incidences of long term (2+ years) moderate or severe bowel problems

42% reduction in relative risk of developing a secondary malignancy

**Significantly fewer** reports of gastrointestinal, genitourinary, endocrine, or "other" complications

### **Rectal/Anal**

More than 50% reduction in radiation dose to critical structures including bone marrow

#### **Overall 31% relative reduction** in occurrence of secondary cancers after treatment



\*References available upon request. Results from separate studies compared in some instances. The benefits of proton therapy for each individual patient will vary based on their individual diagnosis. A personal consultation with a proton-trained physician is recommended in all cases.

Brain/Head & Neck

45% reduction in overall risk of needing a feeding tube for nasopharyngeal cancer

27% reduction in overall risk of needing a feeding tube for oropharyngeal cancer

44% increase of relative 5-year disease free survival rate for nasal and paranasal sinus cavity cancers

50% overall increase of disease control for chordomas

Less side effects during first 3 months after treatment, quicker return to normal function

50% less likely to have secondary tumor from treatment

#### Breast

Delivers 8-18 times less overall radiation to the heart than IMRT

**50-83% less** relative risk of heart attack or another major coronary event depending on age

50% reduction of clinically significant radiation doses to the heart

97% of partial breast irradiation patients experience no breast tumor recurrence at 5 years

90% of cases result in good to excellent cosmetic outcomes at 5 years

(Hepatocellular) 58% higher overall survival rate (2 years)


> **Bile Duct** 54% higher overall survival (4 years)

**Sarcoma 49-75%** reduction in complications

# II - 2. Rationale for in-vivo imaging in proton RT

Target volumes and organ motion: tumor displacement

• Breathing (intrafraction)




Engelsman and Bert 2011 Lüchtenborg PhD 2012

# II - 2. Rationale for in-vivo imaging in proton RT

Target volumes and organ motion: patient displacement/deformation

• Mispositioning (interfraction)




Engelsman and Bert 2011 Lüchtenborg PhD 2012


# II - 2. Rationale for in-vivo imaging in proton RT

Target volumes and organ motion: cavity filling/wall thickening

• Tissue-density modification (interfraction)




### Engelsman and Bert 2011 Lüchtenborg PhD 2012




region without rotation of beam source.

- 3.1 Filling of nasal cavity Head irradiation (NCAT)
  - ① Sphenoid region
  - Treatment plan:
    - Irradiation of a hypothetical tumor located in the sphenoid bone region
    - Empty nasal cavity (air-filled)
  - Compromised treatment:
    - Filled nasal cavity with PMMA-like material
    - Under-range shift of 14 mm
    - o Possible causes:
      - Patient cold → presence of mucus
      - Response after irradiation → edema, tissue swelling
      - Tumor growth




II - 3. The multi-slat concept for prompt-gamma imaging in proton RT




3.2 Change of brain density due to fractionated RT

• Conjecture: brain tissue hypo/hyperdense due to fractionated RT Denham et al Radiother Oncol 2002




- II 3. The multi-slat concept for prompt-gamma imaging in proton RT
  - 3.2 Change of brain density due to fractionated RT
  - Conjecture: brain tissue hypo/hyperdense
  - Corresponding dose distributions (protons):




II - 3. The multi-slat concept for prompt-gamma imaging in proton RT

3.2 Change of brain density due to fractionated RT

- Conjecture: brain tissue hypo/hyperdense
- Corresponding dose profiles (protons):




- II 3. The multi-slat concept for prompt-gamma imaging in proton RT
  - 3.2 Change of brain density due to fractionated RT
  - Conjecture: brain tissue hypo/hyperdense
  - Monte Carlo results with proposed detector (Geant4):




3.3 Prostate: patient mispositioning Pelvis irradiation (NCAT)


### Prostate

- Treatment plan:
  - Irradiation of a hypothetical tumor in the prostate
- Compromised treatment:
  - o Misalignment
    - →Patient 1 cm to ventral
  - Dose proximal displacement
    - → tumor underdosage
  - Possible causes:
    - Mispositioning
    - Patient weight change






## II - 4. In-beam time-of-flight PET for proton RT




## II - 4. In-beam time-of-flight PET for proton RT

A full simulation with an arbitrary single beamlet



Starting position: (0, -155, 0) Direction: Y (gantry angle of 180 degrees) Energy: 131 MeV Beamlet spread size: 8.42 mm sigma Beamlet duration: 4 ms

## II - 4. In-beam time-of-flight PET for proton RT



# Thank you for your attention

- The authors acknowledge the informatics support from the staff of the high-performance computing clusters of the University of Coimbra and Delft University of Technology (thousands of hours of parallel computation).
- P. Cambraia Lopes (The Netherlands) was supported by grant no. SFRH/BD/73705/2010 from FCT – Fundação para a Ciência e a Tecnologia, Lisbon, Portugal.
- H. Simões and P. Crespo were partly supported by the project "Radiation for Life", co-funded by QREN—FEDER under the Sistema de Incentivos à Investigação e Desenvolvimento Tecnológico (CENTRO-07-ST24-FEDER-002007).
- This work was funded in part by the Foundation for Fundamental Research (FOM), The Netherlands (grant no. 09NIG18), and by the European Union Seventh Framework program (grant agreements nos. 241851 and 264552).
- P. Segars (USA) is acknowledged for providing the NCAT digital phantom.
- M. Pinto (Germany) is acknowledged for support on the simulation code.
- Funding:

LIP, July 6<sup>th</sup>, 2023









UNIÃO EUROPEIA Fundos Europeus Estruturais e de Investimento